Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$1.379M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
3.11%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
-$3.194M
Q3 2024
Cash
Q3 2024
P/E
-3.308
Nov 29, 2024 EST
Free Cash Flow
-$295.0K
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020
Revenue $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020
Revenue $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020
Selling, General & Admin $1.907M $3.476M $597.3K $48.50K
YoY Change -45.13% 482.0% 1131.51%
% of Gross Profit
Research & Development $139.7K $266.9K $73.34K $5.750K
YoY Change -47.68% 263.99% 1175.39%
% of Gross Profit
Depreciation & Amortization $3.630K $3.321K $0.00
YoY Change 9.3%
% of Gross Profit
Operating Expenses $2.051M $3.746M $670.6K $54.25K
YoY Change -45.26% 458.66% 1136.15%
Operating Profit -$2.051M -$3.746M -$670.6K
YoY Change -45.26% 458.66%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020
Pretax Income -$2.051M -$3.746M -$670.6K -$54.25K
YoY Change -45.26% 458.66% 1136.15%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.051M -$3.746M -$670.6K -$54.25K
YoY Change -45.26% 458.66% 1136.15%
Net Earnings / Revenue
Basic Earnings Per Share -$0.18 -$0.34 -$0.07
Diluted Earnings Per Share -$0.18 -$0.34 -$0.07 -$0.01

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020
Cash & Short-Term Investments $21.48K $734.0K
YoY Change -97.07%
Cash & Equivalents $21.48K $734.0K
Short-Term Investments
Other Short-Term Assets $108.4K $198.0K
YoY Change -45.28%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $129.9K $932.0K $1.353M $1.365M
YoY Change -86.07% -31.13% -0.86%
Property, Plant & Equipment $4.050K $7.680K
YoY Change -47.27%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $4.050K $7.680K $0.00 $0.00
YoY Change -47.27%
Total Assets $133.9K $939.7K $1.353M $1.365M
YoY Change
Accounts Payable $578.4K $311.8K $388.7K $0.00
YoY Change 85.48% -19.77%
Accrued Expenses $156.4K $518.6K $123.2K $42.04K
YoY Change -69.84% 321.03% 193.01%
Deferred Revenue
YoY Change
Short-Term Debt $55.68K $106.6K $0.00 $0.00
YoY Change -47.74%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.245M $1.079M $702.7K $55.37K
YoY Change 108.06% 53.58% 1169.1%
Long-Term Debt $0.00 $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00 $0.00
YoY Change
Total Liabilities $2.245M $1.079M $702.7K $55.37K
YoY Change 108.06% 53.58% 1169.1%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020
Basic Shares Outstanding 11.35M shares 11.02M shares 9.999M shares
Diluted Shares Outstanding 11.35M shares 11.02M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $4.5624 Million

About Accustem Sciences Inc.

AccuStem Sciences, Inc. is a clinical stage diagnostics company, which engages in medical practice activities. The company is headquartered in New York City, New York and currently employs 3 full-time employees. The company went IPO on 2022-03-01. The firm is focused on developing and commercializing a suite of genomic tests that support decision-making along the entire continuum of oncology care. The firm's product candidate is StemPrintER, a 20-gene prognostic assay intended to predict the risk of distant recurrence (DR) in luminal (ER+/HER2-negative) breast cancer patients. In addition, the Company is focused on offering ancillary commodity testing (hereditary genetic testing, somatic mutation testing) that augments its assays and provides additional information to patients and physicians throughout the patient care continuum. The firm also holds licensing rights for the MicroRNA Signature Classifier (MSC) test, which is designed to help determine whether lung nodules identified by low-dose computed tomography (LDCT) screening are benign or malignant. The firm's wholly owned subsidiary is StemPrintER Sciences Limited.

Industry: Pharmaceutical Preparations Peers: BioCardia, Inc. Apexigen, Inc. Innovation Pharmaceuticals Inc. Inhibitor Therapeutics, Inc. Finch Therapeutics Group, Inc. Galera Therapeutics, Inc. NAVIDEA BIOPHARMACEUTICALS, INC. ORGANOVO HOLDINGS, INC. ProtoKinetix, Inc.